17th Biennial EBV Meeting @ Switzerland (Aug/8-Aug/12)

Session 7: T, NK and B cell lymphomas, 2:30PM-
Chairpersons:
Yasuaki Harabuchi, Asahikawa Medical University, Japan
Bettina Kempkes, Helmholtz Institute Munich, Germany

1. Comprehensive genetic study of chronic active EBV infection Takayuki Murata, Nagoya University, Japan
2. Primary marginal zone lymphomas of the meningeal dura: expanding the spectrum of EBV-related lymphoproliferative disease
 Genevieve Crane, Johns Hopkins University, Baltimore, USA
3. EBNA-3C is not essential for EBV-induced lymphoma formation in a humanized mouse model
 Shannon Kenney, University of Wisconsin, Madison, USA
4. Novel insights into chronic active Epstein Barr virus infection (CAEBV). Claire Shannon-Lowe, University of Birmingham, UK
5. 
In vitro and in vivo effects of proteasome inhibitor bortezomib on Epstein-Barr virus-positive T- or NK-cell lymphoproliferative diseases
Haruna Shibayama, Tokyo Medical and Dental University, Japan
6. Regulation of CDK1 and Survivin by EBV-encoded LMP1 in nasal NK/T-cell lymphoma cells 
Seigo Ueda, Asahikawa Medical University, Japan

Session 8: Double infection of EBV with other pathogens, 16:30-
Chairpersons: Sankar Swaminathan, University of Utah, Salt Lake City, USA
Erle Robertson, University of Pennsylvania, Philadelphia, USA

1. A Humanized Mouse Model of AIDS-associated EBV-driven lymphomagenesis Donal McHugh, University of Zürich, Switzerland
2. 
Impact of early-life pathogen exposure on the development of human T lymphocytes: Implications for Epstein-Barr virus and malaria co-infections and the etiology of endemic Burkitt lymphoma
Yves Falanga, University of Massachussetts Medical School, Worcester, USA
3. NFATc1 activates an EBV BZLF1 promoter variant associated with human malignancies, leading to enhanced lytic reactivation in response to BCR signaling
 Jillian Bristol, University of Wisconsin, Madison, UK
4. LMP1 specifically activates MAPKinases through IkappaB kinase 2 (IKK2) and the oncogenic serine/threonine kinase Tpl2
 Stefanie Voigt, Helmholtz Center Munich, Germany
5. 
Genetic Evidence that EBNA-LP is Essential for EBV Transformation of Umbilical Cord but not Adult B Cells, and Modulates EBNA2 Target Genes. Agnieszka Szymula, Imperial College London, UK
6. Xenografting nasopharyngeal carcinoma tumor tissues into immunodeficient mice are vulnerable to form lymphomas associated with Epstein–Barr virus Fenggang Yu, National University of Singapore, Singapore 另外加拿大group也發了一篇類似的 (Human Solid Tumor Xenografts in Immunodeficient Mice Are Vulnerable to Lymphomagenesis Associated with Epstein-Barr Virus 2012 PLoS One)

Henle Lecture 2016, Plenary lecture hall KOH-B-10
Chairperson: Christian Münz, University of Zürich, Switzerland
Lecturer: Wolfgang Hammerschmidt, Helmholtz Center Munich, Germany

Thursday, 2016/08/11 
Session 9: Burkitt’s and Hodgkin’s lymphoma, 9AM-
Chairpersons:
Andrew Bell, University of Birmingham, UK
Ann Moormann, University of Massachusetts Medical School, Worcester, USA

1. Gene expression and mutation analysis of endemic Burkitt Lymphoma from Western Kenya
 Yasin Kaymaz, University of Massachusetts Medical School, Worcester, USA
2. Characterization of EBV and AFB1 epigenetic signatures in endemic Burkitt’s lymphoma-derived cell lines. 
Rosita Accardi, IARC, Lyon, France
3. Characterization of Epstein Barr virus transcription profile in endemic Burkitt Lymphoma
 Maria Raffaella Ambrosio, University of Siena, Italy
4. 
EBV-encoded miRNA expression in EBER-negative Burkitt lymphoma Pier Paolo Piccaluga, University of Bologna, Italy
5. Insights into the mechanism of apoptosis inhibition by the viral Bcl-2 homologue, BHRF1
 Leah Fitzsimmons, University of Birmingham, UK 
6. BET Bromodomain inhibition selectively targets the Epstein-Barr virus oncogene LMP1 while promoting virus-specific, adaptive anti-tumor activity. Emily Smith, Ohio State University, Columbus, USA

Session 10: Nasopharyngeal carcinoma and other epithelial cell tumors, 11:15-
Chairpersons: George Tsao, University of Hong Kong, China
Mu-Cheng Zeng, Sun Yat-Sen University, Guangzhou, China

1.   
2. Secondary prevention of nasopharyngeal carcinoma: Five-year field trial of a new screening program
 Mingfang Ji, Cancer Research Institute of Zhongshan City, China
6. Production and characterization of monoclonal antibodies neutralizing galectin- 9 for immune restoration in nasopharyngeal carcinomas and other human malignancies
Pierre Busson, Gustave Roussy Institute of Oncology, Villejuif, France (same tile and author as those in GRC NPC)

Session 11: EBV and autoimmunity, 17:30-
Chairpersons: Alberto Ascherio, Harvard University, Boston, USA
David Thorley-Lawson, Tufts University, Boston, USA

1. EBV/lytic infection underlies the activation of the innate immune response in infected scleroderma monocytes 
G. Alessandra Farina, Boston University School of Medicine, USA
2. The antibody response to Epstein-Barr virus in multiple sclerosis is increased only to selected antigens
 John Lindsey, University of Texas HSC Houston, USA
3. 
Krüppel-associated Box (KRAB)-associated protein (KAP)-1 is repressed and post-translationally modified early during Epstein-Barr virus lytic cycle
 Eric Burton, Stony Brook University, USA
4. Global transcript structure resolution of Epstein-Barr virus lytic transcriptome through multi-platform data integration 
Erik Flemington, Tulane University, USA
6. Identification of novel host proteins that interact with the Epstein Barr virus large tegument protein (BPLF1) encoding cysteine protease 
Soham Gupta, Karolinska Institutet, Stockholm, Sweden (In GRC meeting, Wed Poster #11 講BPLF1 和Pol eta, Whitehurst CB, UNC Chapel Hill)

Friday, 2016/08/12
Session 12: Innate immunity to EBV, 10:30AM-
Chairpersons:
Emmanuel Wiertz, University Medical Center Utrecht, The
Netherlands


Fred Wang, Harvard Medical School, Boston, USA

1. The Role of Dendritic Cell Subsets in the Immune Detection of Epstein Barr Virus
 Cornelia Gujer, University of Zurich, Switzerland 
2. 
Epstein-Barr Virus miRNAs attenuate the cellular response to type I interferon Jasper Soppe, University Medical Center Utrecht, The Netherlands
3. BamHI-A rightward transcripts function as nuclear long non-coding RNA and modulate host gene expression by interacting with CBP
Rob Verhoeven, University of Hong Kong, China
4. 
Cognate HLA absence diminishes human NK cell education in trans Vanessa Landtwing, University of Zurich, Switzerland
5. Distinct NK cells subset expansion in EBV-infected children with endemic Burkitt lymphoma.
 Catherine Forconi, University of Massachusetts Medical School, USA
6. The role of myeloid derived suppressor cells in Epstein Barr virus infection and associated tumorigenesis
 Christine Engelmann, University of Zurich, Switzerland  純粹是看

Session 13: Adaptive immunity to EBV, 13:30PM-Chairpersons:
Josef Mautner, Helmholtz Center Munich, Germany
Jaap Middeldorp, Free University Amsterdam, The Netherlands

1. Novel application of protein microarray technology to examine the comprehensive humoral immune response to Epstein-Barr Virus in relation to nasopharyngeal carcinoma
 Anna Coghill, National Cancer Institute, Bethesda, USA
2. Changes in EBV lytic-antigen target choice by CD8+ T cells during different phases of infection
 Calum Forrest, University of Birminghan, UK
3. Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses early in infection
 Takanobu Tagawa, Helmholtz Center Munich, Germany
4. CD8+ T cells express inhibitory receptors but retain functionality in a humanized mouse model of Epstein-Barr virus infection
 Bithi Chatterjee, University of Zurich, Switzerland (這是什麼意思)
5. Role of Epstein-Barr virus-encoded microRNAs in cytotoxic T lymphocytes (CTL) immune evasion
 Manuel Albanese, Helmholtz Center Munich, Germany 
6. Epstein-Barr virus strain heterogeneity impairs T cell immunity Josef Mautner, Helmholtz Center Munich, Germany

Session 14: Vaccines and anti-viral therapies, 15:30PM-
Chairpersons:
Richard Ambinder, Johns Hopkins University, Baltimore, USA
Rajiv Khanna, Queensland Institute of Medical Research, Brisbane, Australia 

1. Self-assembling Epstein-Barr virus nanoparticle vaccines elicit antibodies that potently neutralize virus infection of B cell and epithelial cells
 Wei Bu, National Institutes of Allergy and Infectious Diseases, Bethesda, USA
2. Pathway to Discovery of Valpromide, a Novel Anti-Viral Compound that Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus
 George Miller, Yale University, New Haven, USA
3. 
Combining antigen formulations for vaccination against EBV-related malignancies
 J ulia Rühl, University of Zurich, Switzerland
4. 
A gp350 neutralizing antibody does not block EBV type 2 infection of B cells: implication for vaccine development.
Rosemary Rochford, University of Colorado, Aurora, USA (這是什麼意思)
5. Primary EBV infection induces expansion of polyfunctional virus-specific CD4+ T cells with cytotoxic capacity 
Heather Long, University of Birmingham, UK